Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy : Future Perspectives

• Autore: Vermehren Charlotte
• Pubblicazione: Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
• Descrizione fisica: 1 online resource (224 p.)
• Soggetto topico: Manufacturing industries; Medicine and Nursing
• Soggetto non controllato: 2019 Beers criteria; 5'nuclease assay; 80 and over; abacavir; acute kidney injury; adverse drug reaction; adverse drug reactions; aged; allopurinol; antidepressants; antiepileptic drugs; antipsychotics; appropriateness; bleeding; children; chronic; clinical pharmacist; clozapine; CNV; copy number variation; cost-effectiveness; CYP1A2; CYP2D6; CYP2D7P; CYP2D8P; cytochrome P450; cytochromes; deprescribing; deprescriptions; determinants; digital decision-support; digital health; DOACs; drug hypersensitivity; drug information service; drug interaction checkers; drug metabolization; drug-drug interactions; drug-gene interactions; early biomarker; electronic medical record; electronic prescribing; emergency department; Ethiopia; exosomes; extracellular vesicles; flucloxacillin; general practice; genotyping; health outcomes; health services research; high resolution melting; HLA; hospital pharmacy service; HRM; loxapine; medication adherence; medication optimization; medication reconciliation; medication review; medication-based risk score; microvesicles; multimorbidity; nursing homes; olanzapine; older adults; older patients; outpatient; personalized medicine; persons with diabetes; pharmacogene expression; pharmacogenetics; pharmacogenomics; phenprocoumon; plasma neutrophil gelatinase-associated lipocalin; polypharmacy; population-based; potentially inappropriate medication use; prevalence; process evaluation; quality of life; shared medication record; SLCO1B1; soluble urokinase plasminogen activator receptor; thromboembolism; utility; youth
• Persona (resp. second.): WestergaardNiels; VermehrenCharlotte
• Sommario/riassunto: Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug-drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug-drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug-gene and drug-drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.
• Altri titoli varianti: Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy
• Titolo autorizzato: Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910595072903321
• Lo trovi qui: Univ. Federico II